Call for Applications: COVAX Seeks Experts for Independent Panel on Evidence-Based Vaccine Decision-Making



COVAX is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi), the World Health Organization (WHO) and UNICEF – working in collaboration with sovereign governments, society civil society, industry and other international organizations to support equitable access to COVID-19 vaccines. Since the start of the pandemic, COVAX has supported and accelerated the development, manufacturing, stockpiling, supply and equitable allocation of COVID-19 vaccines to enable the largest and fastest deployment of lifesaving tools. the history of global health. As of July 2022, COVAX has shipped over 1.6 billion doses to 146 countries.

The COVAX Pillar was launched in April 2020 in response to the COVID-19 pandemic, with the goal of providing innovative and equitable access to COVID-19 vaccines. As part of its role, Gavi coordinates the COVAX Facility, responsible for pooled procurement and equitable distribution of safe, effective and good quality COVID-19 vaccines selected through scientific evaluation from the broadest vaccine portfolio. and the most diverse in the world.

COVAX Independent Product Group Now Open for Applications

In October 2020, CEPI and Gavi created the COVAX Independent Product Group (IPG). The IPG has operated successfully as a diverse and globally representative committee to provide independent advice to the COVAX pillar and the COVAX facility, primarily; a) support the COVAX facility in conducting evidence-based assessments to build a diverse portfolio of vaccines to ensure equitable access b) on the identification and selection of vaccine candidates likely to meet threshold criteria of purchase by installation, and thereafter, if these criteria are met.

Given the evolving pandemic situation, the COVAX facility will continue to adapt and innovate to changing circumstances and needs, providing the opportunity to renew its membership in this diverse advisory group to a ) continue to advise on the development of new and improved COVID-19 vaccines and b) provide technical support on COVID-19 vaccination programs and vaccine needs for the current pandemic situation and a possible future endemic phase .

The COVAX facility is seeking expressions of interest from subject matter experts to join the COVAX Independent Product Group.

Members of the Independent Product Group will review data and information on candidate COVID-19 vaccines that may be suitable for supply by the COVAX facility, monitor changes and evolution of vaccines to respond to a) the virus and evolving SARS-COV-2 subvariants, b) modification of human immunity, c) programmatic needs and objectives – particularly those present in developing countries, as well as providing recommendations to the COVAX Facility.

As part of this work, IPG members will interact with the COVAX Vaccine Development and Optimization Task Force, which is responsible for making R&D and manufacturing investment decisions for the COVAX portfolio. candidate vaccines and enabling scientific activities.

We are currently looking for 5-7 experts to join the COVAX Independent Product Group, with diverse and global expertise in the following areas:

  • Coronavirus vaccines and/or COVID-19 vaccines
  • Animal models and assays for vaccine evaluation
  • Clinical evaluation of vaccines, including evaluation of vaccines in large randomized clinical trials in various geographical settings
  • Regulatory expertise in evaluating vaccines from different regions
  • Vaccine manufacturing and GMP issues
  • Expertise in epidemiology/public health/health policy
  • Expertise in viral evolution and the resulting immunological escape
  • Expertise in immunization programs and service delivery
  • Vaccine safety assessment and monitoring

The deadline for submitting applications is October 22, 2022. Please share this announcement with your networks. Applicants are requested to email their expression of interest and curriculum vitae to: [email protected]

Further information and details on how to apply are available here.

#Nobody is safe until everyone is safe

We are committed to fostering a fair, equitable and diverse culture, free from racism and discrimination, in which all staff, partners and stakeholders feel empowered, safe and heard.

Source link


About Author

Comments are closed.